Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3

CD28/B7 SYSTEM OF T CELL COSTIMULATION

Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717

LAG-3, a novel lymphocyte activation gene closely related to CD4.

Triebel, F., Jitsukawa, S., Baixerás, E., Roman‐Roman, S., Genevée, C., Viégas-Pèquignot, E., & Hercend, T. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.5.1393 · Cited by 936

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.

Baixerás, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., & Piatier‐Tonneau, D. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.2.327 · Cited by 397

CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins

Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391

Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class.

Gronwald, R. G., Grant, F. J., Haldeman, B. A., Hart, C. E., O’Hara, P. J., Hagen, F. S., Ross, R., Bowen‐Pope, D. F., & Murray, M. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3435 · Cited by 316

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., Tayar, N. E., Maigret, B., Dréano, M., & Triebel, F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5744 · Cited by 308

CD3/TCR complex‐associated lymphocyte activation gene‐3 molecules inhibit CD3/TCR signaling

Hannier, S., Tournier, M., Bismuth, G., & Triebel, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4058 · Cited by 248

Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells

Gosset, P., Charbonnier, A.-S., Delerive, P., Fontaine, J., Staels, B., Pestel, J., Tonnel, A., & Trottein, F. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10 · Cited by 225

Retroviral-Mediated Transfer of the Green Fluorescent Protein Gene Into Murine Hematopoietic Cells Facilitates Scoring and Selection of Transduced Progenitors In Vitro and Identification of Genetically Modified Cells In Vivo

Persons, D. A., Allay, J. A., Allay, E. R., Smeyne, R. J., Ashmun, R. A., Sorrentino, B. P., & Nienhuis, A. W. (1997) · Blood · doi:10.1182/blood.v90.5.1777 · Cited by 222

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand

Huard, B., Gaulard, P., Faure, F., Hercend, T., & Triebel, F. (1994) · Immunogenetics · doi:10.1007/bf00241263 · Cited by 202

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

Chocarro, L., Bocanegra, A., Blanco, E., Fernández, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Piñeiro‐Hermida, S., Vera, R., et al. (2022) · Cells · doi:10.3390/cells11152351 · Cited by 73

PDL1‐positive exosomes suppress antitumor immunity by inducing tumor‐specific CD8+ T cell exhaustion during metastasis

Chen, J., Song, Y., Miao, F., Chen, G., Zhu, Y., Wu, N., Pang, L., Chen, Z., & Chen, X. (2021) · Cancer Science · doi:10.1111/cas.15033 · Cited by 70

A signal-decreased electrochemical immunosensor for the sensitive detection of LAG-3 protein based on a hollow nanobox-MOFs/AuPt alloy

Xu, W., Qin, Z., Hao, Y., He, Q. Z., Chen, S., Zhang, Z., Peng, D., Wen, H., Chen, J., Qiu, J., et al. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.05.010 · Cited by 67

CD6, a Rheostat-Type Signalosome That Tunes T Cell Activation

Gonçalves, C. M., Henriques, S. N., Santos, R. F., & Carmo, A. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02994 · Cited by 69

Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies

Bhandaru, M., & Rotte, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_4 · Cited by 68

CD4+CD25+ REGULATORY T CELLS IN HEALTH AND DISEASE

Liu, H., & Leung, B. P. L. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04401.x · Cited by 67

Reverting Immune Suppression to Enhance Cancer Immunotherapy

Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 71

Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy

Bangayan, N. J., Wang, L., Sojo, G. B., Noguchi, M., Cheng, D., Ta, L. H., Gunn, D., Mao, Z., Liu, S., Yin, Q., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312374120 · Cited by 68

Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment

Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66

Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma

Lin, M., He, J., Zhang, X., Sun, X., Dong, W., Zhang, R., Xu, Y., & Lv, L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164528 · Cited by 65

LAG‐3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors

Buisson, S., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2004.02087.x · Cited by 65

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity

Burnell, S. E. A., Capitani, L., MacLachlan, B. J., Mason, G. H., Gallimore, A., & Godkin, A. J. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab025 · Cited by 64

Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion

Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78

Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations

Sun, H., Sun, C., & Xiao, W. (2013) · Cytokine · doi:10.1016/j.cyto.2013.09.016 · Cited by 65

Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints

Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 63

Progress of immune checkpoint LAG‑3 in immunotherapy (Review)

Shan, C., Li, X., & Zhang, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12070 · Cited by 60

Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis

Guo, X.-Z. J., Dash, P., Calverley, M., Tomchuck, S. L., Dallas, M. H., & Thomas, P. G. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.54 · Cited by 59

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma

Fröhlich, A., Sirokay, J. D., Fietz, S., Vogt, T. J., Dietrich, J., Zarbl, R., Florin, M., Kuster, P., Saavedra, G., Valladolid, S. R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102962 · Cited by 61

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy

Ibrahim, R., Saleh, K., Chahine, C., Khoury, R., Khalife, N., & Cesne, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11071878 · Cited by 60

Recent advances in immunotherapy for hepatocellular carcinoma

Khan, A. A., Liu, Z., & Xu, X. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.06.010 · Cited by 56

Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses

Patsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 57

T cell exhaustion in cancer: Mechanisms and clinical implications

Wang, J., Xu, Y., Huang, Z., & Lu, X. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26645 · Cited by 56

LAG3 (CD223) and autoimmunity: Emerging evidence

Hu, S., Liu, X., Li, T., Li, Z., & Hu, F. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102504 · Cited by 53

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes

Pesce, S., Trabanelli, S., Vito, C. D., Greppi, M., Obino, V., Guolo, F., Minetto, P., Bozzo, M., Calvi, M., Zaghi, E., et al. (2020) · Cancers · doi:10.3390/cancers12123504 · Cited by 53

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors

Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53

Current concepts of non-coding RNA regulation of immune checkpoints in cancer

Smolle, M. A., Prinz, F., Calin, G. A., & Pichler, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.09.007 · Cited by 51

Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction

Bhagwat, B., Cherwinski, H. M., Sathe, M., Seghezzi, W., McClanahan, T. K., Malefyt, R. D. W., & Willingham, A. T. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.02.003 · Cited by 51

Gene of the month: lymphocyte-activation gene 3 (LAG-3)

Lythgoe, M. P., Liu, D., Annels, N. E., Krell, J., & Frampton, A. E. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207517 · Cited by 49

Emerging immune checkpoints for cancer therapy

Li, X., Hu, W., Zheng, X., Zhang, C., Du, P., Zheng, Z., Yang, Y., Wu, J., Ji, M. Q., Jiang, J., et al. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1071918 · Cited by 50

Immune Checkpoints in Cancers: From Signaling to the Clinic

Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 51

Dominant immune cells in pregnancy and pregnancy complications: T helper cells (TH1/TH2, TH17/Treg cells), NK cells, MDSCs, and the immune checkpoints

Esparvarinha, M., Madadi, S., Aslanian‐Kalkhoran, L., Nickho, H., Dolati, S., Pia, H., Danaii, S., Taghavi, S., & Yousefi, M. (2022) · Cell Biology International · doi:10.1002/cbin.11955 · Cited by 47

A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases

Angin, M., Brignone, C., & Triebel, F. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900823 · Cited by 48

The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy

Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D., & Rodríguez-García, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298571 · Cited by 48

Lymphocyte Activation Gene-3 (LAG-3) Negatively Regulates Environmentally-Induced Autoimmunity

Jha, V., Workman, C. J., McGaha, T. L., Li, L., Vas, J., Vignali, D. A. A., & Monestier, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104484 · Cited by 48

Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis

Jiménez-Alejandre, R., Ruiz‐Fernández, I., & Martín, P. (2022) · Cancers · doi:10.3390/cancers14184494 · Cited by 50

Inhibitory co-receptor Lag3 supports Foxp3+ regulatory T cell function by restraining Myc-dependent metabolic programming

Kim, D., Kim, G., Yu, R., Lee, J., Kim, S., Gleason, M. R., Qiu, K., Montauti, E. I., Wang, L. L., Fang, D., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.008 · Cited by 48

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma

Albrecht, L. J., Livingstone, E., Zimmer, L., & Schadendorf, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01406-4 · Cited by 49

The New Era of Cancer Immunotherapy

Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 46

Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function

Silberstein, J. L., Du, J., Chan, K.-W., Frank, J. A., Mathews, I. I., Kim, Y. B., You, J., Qiao, L., Liu, J., Philips, E. A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310866121 · Cited by 45

Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases

Gertel, S., Polachek, A., Elkayam, O., & Furer, V. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103085 · Cited by 44

Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity

Du, J., Chen, H., You, J., Hu, W., Liu, J., Qiao, L., Zhang, Y., Gao, J., Lin, M., Foster, C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.004 · Cited by 50

LAG-3: a very singular immune checkpoint

Lui, Y., & Davis, S. J. (2018) · Nature Immunology · doi:10.1038/s41590-018-0257-1 · Cited by 43

The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation

Köhler, N., Ruess, D. A., Kesselring, R., & Zeiser, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634435 · Cited by 45

Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?

Khosroshahi, L. M., Parhizkar, F., Kachalaki, S., Aghebati‐Maleki, A., & Maleki, L. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107935 · Cited by 43

Modulation of Redox Balance Leaves Murine Diabetogenic TH1 T Cells “LAG-3-ing” Behind

Delmastro-Greenwood, M. M., Styche, A. J., Trucco, M., Workman, C. J., Vignali, D. A. A., & Piganelli, J. D. (2012) · Diabetes · doi:10.2337/db11-1591 · Cited by 41

Potential New Therapeutic Approaches for Renal Cell Carcinoma

Yang, D. C. H., & Chen, C. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.010 · Cited by 45

On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment

Tundo, G. R., Sbardella, D., Lacal, P. M., Graziani, G., & Marini, S. (2019) · Chemotherapy · doi:10.1159/000500902 · Cited by 41

Emerging roles of Egr2 and Egr3 in the control of systemic autoimmunity

Morita, K., Okamura, T., Sumitomo, S., Iwasaki, Y., Fujio, K., & Yamamoto, K. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kew342 · Cited by 39

Checkpoint Inhibitors: Applications for Autoimmunity

Tocheva, A. S., & Mor, A. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0740-z · Cited by 39

Roles, function and relevance of LAG3 in HIV infection

Graydon, C. G., Balasko, A. L., & Fowke, K. R. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007429 · Cited by 39

Prognostic role of immune cells in hepatocellular carcinoma

Sachdeva, M., & Arora, S. K. (2020) · EXCLI journal · doi:10.17179/excli2020-1455 · Cited by 39

The basic biology of NK cells and its application in tumor immunotherapy

Jiang, P., Jing, S., Sheng, G., & Jia, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420205 · Cited by 43

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB

Manso, T., Kushwaha, A., Abdollahi, N., Duroux, P., Giudicelli, V., & Κοσσίδα, Σ. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129323 · Cited by 42

Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications

Wang, J., Wang, Y., Jiang, X., Xu, M., Wang, M., Wang, R., Zheng, B., Chen, M., Qi, K., & Long, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216758 · Cited by 40

Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

Ming, Q., Antfolk, D., Price, D. A., Manturova, A., Medina, E., Singh, S., Mason, C. C., Tran, T. H., Smalley, K. S. M., Leung, D. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51930-5 · Cited by 39

Advances in LAG3 cancer immunotherapeutics

Adam, K. R., Butler, S. C., Workman, C. J., & Vignali, D. A. A. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.10.009 · Cited by 37

Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets

van Herk, E. H., & Velde, A. A. T. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13342 · Cited by 37

Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects

Long, L., Zhao, C., Muqimova, O., Zhao, X., Yang, J. L., & Chen, H. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-018-00746-5 · Cited by 33

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma

Veigas, F., Mahmoud, Y. D., Merlo, J. P., Rinflerch, A., Rabinovich, G. A., & Girotti, M. R. (2021) · Cancers · doi:10.3390/cancers13051018 · Cited by 41

Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-viral CD8+ T Cells and Protect Against Recurrent Ocular Herpes Simplex Infection and Disease

Roy, S., Coulon, P.-G. A., Srivastava, R., Vahed, H., Kim, G. J., Walia, S. S., Yamada, T., Fouladi, M. A., Ly, V. T., & BenMohamed, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02922 · Cited by 35

Translation of cancer immunotherapy from the bench to the bedside

Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 35

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges

Regzedmaa, O., Zhang, H., Liu, H., & Chen, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s204577 · Cited by 34

Molecular characterization of HLA class II binding to the LAG‐3 T cell co‐inhibitory receptor

MacLachlan, B. J., Mason, G. H., Greenshields‐Watson, A., Triebel, F., Gallimore, A., Cole, D. K., & Godkin, A. J. (2020) · European Journal of Immunology · doi:10.1002/eji.202048753 · Cited by 34

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Pitts, S. C., Schlom, J., & Donahue, R. N. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03074-z · Cited by 36

Control of Regulatory T Cells by Co-signal Molecules

Wing, J. B., Tay, C., & Sakaguchi, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_7 · Cited by 32

Discovery of New Immune Checkpoints: Family Grows Up

Kong, X. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_4 · Cited by 35

The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases

Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 35

The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?

Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33

Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets

Zhou, X., Ren, T., Zan, H., Hua, C., & Guo, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864202 · Cited by 33

Biomechanics of T Cell Dysfunctions in Chronic Diseases

Gunasinghe, S. D., Peres, N. G., Goyette, J., & Gaus, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.600829 · Cited by 33

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

Qi, Y., Chen, L., Liu, Q., Kong, X., Fang, Y., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563258 · Cited by 32

Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions

Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 34

Immune checkpoint receptors in cancer: redundant by design?

Li, J., Ni, L., & Dong, C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.001 · Cited by 31

Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics

Everett, K. L., Kraman, M., Wollerton, F., Zimarino, C., Kmiecik, K., Gaspar, M. A., Pechouckova, S., Allen, N. L., Doody, J. F., & Tuna, M. (2018) · Methods · doi:10.1016/j.ymeth.2018.09.003 · Cited by 31

Lymphocyte‐activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein‐Barr virus‐positive and MLH1‐defective gastric cancer patients

Lv, K., Li, R., Cao, Y., Gu, Y., Liu, X., He, X., Jin, K., Fang, H., Fei, Y., Shi, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33358 · Cited by 32

Inhibitory Immune Checkpoint Molecules and Exhaustion of T cells in COVID-19

Barnova, M., Bobčáková, A., Urdova, V., Kosturiak, R., Kapustova, L., Dobrota, D., & Jeseňák, M. (2021) · Physiological Research · doi:10.33549/physiolres.934757 · Cited by 32

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Huang, X., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 34

Regulatory T Cells in the Tumor Microenvironment

Dadey, R., Workman, C. J., & Vignali, D. A. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_6 · Cited by 32

From T cell “exhaustion” to anti-cancer immunity

Verdeil, G., Marraco, S. A. F., Murray, T. J., & Speiser, D. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.007 · Cited by 31

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors

Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29

Advancement of anti‐LAG ‐3 in cancer therapy

Li, Y., Ju, M., Miao, Y., Zhao, L., Xing, L., & Wei, M. (2023) · The FASEB Journal · doi:10.1096/fj.202301018r · Cited by 29

Prognostic significance of Lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis

Li, R., Qiu, J., Zhang, Z., Qu, C., Tang, Z., Yu, W., Tian, Y., & Tian, H. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03157-5 · Cited by 29

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance

Wei, Y., & Li, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.831407 · Cited by 29

Phytochemicals in regulating PD ‐1/ PD‐L1 and immune checkpoint blockade therapy

Zhong, C., Yang, C., Gao, X., Dong, J., & Zhong, C. (2023) · Phytotherapy Research · doi:10.1002/ptr.8082 · Cited by 30

Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II

Wakamatsu, E., Machiyama, H., Toyota, H., Takeuchi, A., Hashimoto, R., Kozono, H., & Yokosuka, T. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114655 · Cited by 28

Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus

Konnai, S., Suzuki, S., Shirai, T., Ikebuchi, R., Okagawa, T., Sunden, Y., Mingala, C. N., Onuma, M., Murata, S., & Ohashi, K. (2012) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2012.09.005 · Cited by 28

Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives

de Goycoechea, D., Stalder, G., Martins, F., & Duchosal, M. A. (2019) · Journal of Oncology · doi:10.1155/2019/9513701 · Cited by 27

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Chen, Y., Zhu, Y., Kramer, A. B., Fang, Y., Wilson, M., Li, Y.-R., & Yang, L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1135468 · Cited by 26

Elderly dendritic cells respond to LPS/IFN-γ and CD40L stimulation despite incomplete maturation

Gardner, J. K., Cornwall, S. M. J., Musk, A. W., Alvarez, J., Mamotte, C. D. S., Jackaman, C., Nowak, A. K., & Nelson, D. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195313 · Cited by 29

Zinc finger protein ZNF202 structure and function in transcriptional control of HDL metabolism

Schmitz, G., Heimerl, S., & Langmann, T. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200404000-00013 · Cited by 26

Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy

Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 28

Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?

Obeid, J. M., Kunk, P. R., Zaydfudim, V. M., Bullock, T. N. J., Slingluff, C. L., & Rahma, O. E. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2082-z · Cited by 25

Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion

Ascione, A., Arenaccio, C., Mallano, A., Flego, M., Gellini, M., Andreotti, M., Fenwick, C. W., Pantaleo, G., Vella, S., & Federico, M. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0559-x · Cited by 25

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

Zhang, J., Hu, C., Xie, X., Qi, L.-Z., Li, C., & Li, S. (2023) · Vaccines · doi:10.3390/vaccines11030614 · Cited by 25

Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance

Martinov, T., & Fife, B. T. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14106 · Cited by 28

Tipping the balance: inhibitory checkpoints in intestinal homeostasis

Joosse, M. E., Nederlof, I., Walker, L. S. K., & Samsom, J. N. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0113-5 · Cited by 24

Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications

Zhao, L., Wang, H., Xu, K., Liu, X., & He, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001981 · Cited by 24

Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma

Yang, C., Qian, Q., Zhao, Y., Huang, B., Chen, R., Gong, Q., Ji, H., Wang, C., Xia, L., You, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112672 · Cited by 24

Profiling Immune Escape in Hodgkin’s and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining

Péricart, S., Tosolini, M., Gravelle, P., Rossi, C., Traverse‐Glehen, A., Amara, N., Franchet, C., Martin, E., Bezombes, C., Laurent, G., et al. (2018) · Cancers · doi:10.3390/cancers10110415 · Cited by 24

Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors

Ogawa, S., & Abe, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_4 · Cited by 22

The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells

Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 318

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination

Triebel, F. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.001 · Cited by 150

The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells

Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 190

Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)

Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 344

Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)

Li, N., Workman, C. J., Martin, S., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6806 · Cited by 139